1430474-95-5Relevant academic research and scientific papers
The discovery of orally bioavailable tyrosine threonine kinase (TTK) inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as anticancer agents
Liu, Yong,Lang, Yunhui,Patel, Narendra Kumar,Ng, Grace,Laufer, Radoslaw,Li, Sze-Wan,Edwards, Louise,Forrest, Bryan,Sampson, Peter B.,Feher, Miklos,Ban, Fuqiang,Awrey, Donald E.,Beletskaya, Irina,Mao, Guodong,Hodgson, Richard,Plotnikova, Olga,Qiu, Wei,Chirgadze, Nickolay Y.,Mason, Jacqueline M.,Wei, Xin,Lin, Dan Chi-Chia,Che, Yi,Kiarash, Reza,Madeira, Brian,Fletcher, Graham C.,Mak, Tak W.,Bray, Mark R.,Pauls, Henry W.
supporting information, p. 3366 - 3392 (2015/05/05)
The acetamido and carboxamido substituted 3-(1H-indazol-3-yl)benzenesulfonamides are potent TTK inhibitors. However, they display modest ability to attenuate cancer cell growth; their physicochemical properties, and attendant pharmacokinetic parameters, a
KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
-
, (2014/05/07)
The invention is a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).
INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
-
Page/Page column 146; 147, (2013/04/25)
The present teaching provide indazole compounds represented by Structural Formulae (I) or (I') or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as T
